Novo Nordisk inks multimillion-dollar deal with Ventus Therapeutics
The Danish pharmaceutical firm gains exclusive worldwide rights to a number of treatment candidates, one of which is for fatty liver disease NASH, developed by the US-based biotech company.
by marketwire, translated by daniel pedersen
Danish pharmaceutical giant Novo Nordisk has signed a development and license agreement with Ventus Therapeutics, a US-based biotech focused on using small molecules to treat challenging targets, the latter firm announces in a press release.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.